Skip to Main Content

Paper Details

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
Blood Adv
24
2023
Author NameAffiliation
Thorsten BraunService d'Hematologie Clinique Hopital Avicenne-APHP-Universite Paris XIII
Justin M WattsUniversity of Miami Sylvester Comprehensive Cancer Center
Jorge CortesGeorgia Cancer Center, Augusta University
  • 1 - 3

Datasets

Release 1.2